Document Detail

Clinical Experience of Treatment of Metastatic Melanoma and Solid Tumours Adopting a Derivative of Diphtheria Toxin: Cross-reacting Material 197.
MedLine Citation:
PMID:  23422478     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Diphtheria toxin (DT) has shown anticancer activity in both experimental models and humans but its adverse effects stopped further developments. Cross-reacting Material 197 (CRM197) is the product of a single missense mutation (Gly52 to Glu) within fragment A of DT. It has been shown to induce weak toxicity in some cell strains, but it shares immunological properties with native DT. CRM197 commonly acts as an immunological adjuvant, or as an inhibitor of heparin-binding epidermal growth factor. Recently, CRM197 was shown to have promising antitumor activity. To better-define this property, we planned a phase I-II study.
PATIENTS AND METHODS: Twenty-nine patients bearing advanced melanoma (18 cases), and other solid tumors (two ovarian cancer, two sarcoma, two gastrointestinal cancers, one urinary bladder carcinoma, one glioblastoma, one neuroblastoma, one ocular melanoma and one primitive neuroectodermal embriogenic tumor (PNET) were evaluated and 19 of them, sub-divided in cohorts, received the following levels of CRM197: Level 1, 0.3 mg; level 2, 1.0 mg; level 3, 2.5 mg; level 4, 3.5 mg; level 5, 5.0 mg; level 6, 7.5 mg. The drug was given once every two days for 4 times and then, after a 2-week rest period, once every 2 days for 4 times. CRM197 was administered subcutaneously in the abdominal wall.
RESULTS: grade 1-2 common toxicities included fever, chills, fatigue, dizziness, nausea, vomiting and headache, neutrophilia and skin painful reactions appeared regularly at levels 3 and 4 (2.5 mg and 3.5 mg). Vomiting and abdominal pain, skin reaction tachycardia and hypotension appeared in two patients at level 5. At 7.5 mg, we observed a severe grade 3 reaction with hypotension, dyspnea and grade 4 myalgia. This was considered the dose-limiting toxicity. Eleven patients (seven with melanoma and four with other tumors) were treated to evaluate anticancer effects at the maximum tolerated dose (5 mg). Only one patient reported a minor response, lasting eight weeks. Ten patients reported progressive disease.
CONCLUSION: CRM197, injected subcutaneously at 5 mg, elicited a generic inflammatory response causing toxicity, and did not exert a significant degree of antitumor activity in patients with advanced melanoma and solid tumour.
Giammaria Fiorentini; Roberto Banfi; Patrizia Dentico; Sabina Moriconi; Gina Turrisi; Filippo Pelagotti; Susanna Rossi; Francesco Montagnani
Related Documents :
23108698 - A phase i trial of imatinib in combination with mfolfox6-bevacizumab in patients with a...
1891488 - Smoking-cessation treatment combining transdermal nicotine substitution with behavioral...
9712458 - Effect of active and passive cigarette smoking on cyp1a2-mediated phenacetin dispositio...
7837048 - Effect of caffeine and nicotine on avoidance learning in mice: lack of interaction.
17404468 - Dose delivered from varian's cbct to patients receiving imrt for prostate cancer.
16859848 - Validation of large white pig as an animal model for the study of cannabinoids metaboli...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  In vivo (Athens, Greece)     Volume:  27     ISSN:  1791-7549     ISO Abbreviation:  In Vivo     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8806809     Medline TA:  In Vivo     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  197-202     Citation Subset:  IM    
Oncology Unit, Department of Oncology-Hematology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, via Cesare Lombroso 1, 61122 Pesaro (PU), Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The utility of fecal corticosterone metabolites and animal welfare assessment protocols as predictiv...
Next Document:  Abnormalities in Fatty acids in plasma, erythrocytes and adipose tissue in Japanese patients with co...